Immuno-Oncology in Cancer Care is a Fantastic Opportunity for Interventional Oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative

Baère, Thierry De; Tselikas, Lambros; Deschamps, Frédèric; Soria, Jean Charles; Marabelle, Aurélien

doi:10.1007/s00270-018-1935-y

Cited by 7 publications

(7 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RFA is not limited by the number of lung metastases, since a patient with 23 lung metastases has been successfully treated with RFA over a 10-year period, without impending lung function [30]. Moreover, like with radiotherapy, there is increasing interest in the abscopal and immunologic effects following thermal ablation [31]. With the use of newer targeted agents and immunomodulatory agents, optimization of patient selection through sequencing and combining the various treatment options is challenging.…”

Section: Discussionmentioning

confidence: 99%

Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience

et al. 2019

View full text Add to dashboard Cite

BackgroundTo determine safety and efficacy of radiofrequency ablation (RFA) for local treatment of lung metastases of renal cell carcinoma (RCC), sequenced or combined with systemic treatments.MethodsRetrospectively, we studied 53 patients treated by RFA for a maximum of six lung metastases of RCC. The endpoints were local efficacy, overall (OS), disease-free (DFS), pulmonary progression-free (PPFS) and systemic treatment-free (STFS) survivals, complications graded by the CTCAE classification and factors associated with survivals. Potential factors analysed were: clinical and pathological data, tumoral staging of TNM classification, primary tumor histology, Fuhrman’s grade, age, number and size of lung metastases and extra-pulmonary metastases pre-RFA.ResultsOne hundred metastases were treated by RFA. Median follow-up time was 61 months (interquartile range 90–34). Five-year OS was 62% (95% confidence interval (CI): 44–75). Median DFS was 9.9 months (95% CI: 6–16). PPFS at 1 and 3 years was 58.9% (95%CI: 44.1–70.9) and 35.2% (95%CI: 21.6–49.1), respectively. We observed 3% major complications (grade 3 and 4 of CTCAE classification). Local efficacy was 91%. Median STFS was 28.3 months. Thirteen patients (25%) with lung recurrence could be treated by another RFA. T3/T4 tumors had significantly worse OS, PPFS and STFS. Having two or more lung metastases increased the risk of pulmonary progression more than threefold.ConclusionIntegrated to systemic treatment strategy, RFA is safe and effective for the treatment strategy of lung metastasis from RCC with good OS and long systemic treatment-free survival. RFA offers the possibility of repeat procedures, with low morbidity.

show abstract

Section: Discussionmentioning

confidence: 99%

Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience

et al. 2019

View full text Add to dashboard Cite

show abstract

“…CCA represents a heterogeneous group of malignancies arising from the biliary tract, the second most common primary liver cancer and are commonly classified as either perihilar, distal, or intrahepatic (iCCA). 3,79 The carcinogenesis of CCA is yet to be fully understood. It often arises in biliary tissue characterized by chronic inflammation and cholestasis, with a resulting mixture of proinflammatory cytokines, growth factors, and bile acids.…”

Section: Intrahepatic Cholangiocarcinomamentioning

confidence: 99%

“… 2 In liver cancer, LRTs play a major role for both local and advanced stages, although their efficacy can be compromised by tumors’ size and number. 3 …”

Section: Introductionmentioning

confidence: 99%

Synergizing liver systemic treatments with interventional oncology: friend or foe?

Jost

Al-Shatti

Ghosn

et al. 2022

The British Journal of Radiology

Self Cite

View full text Add to dashboard Cite

Interventional radiology techniques provide excellent local tumor control for small tumors in various organs, but several limitations can hamper the oncological outcomes such as the tumor size or the number of lesions. Technical improvements, optimal patient selection and combination with systemic therapies, including immune checkpoint inhibitors, have been successfully developed to overcome these barriers. In this setting, chemotherapy and targeted therapies aim to diminish the tumor burden in addition to local treatments, while immunotherapies may have a synergistic effect in terms of mechanism of action on the tumor cell as well as the immune environment, with multiple treatment combinations being available. Finally, Interventional Radiology treatments often increase tumor antigen exposure to the immune system and thus stimulate a specific antitumor immune response that can act beyond the treated site. Notwithstanding their many benefits, combination treatment may also result in complications, the most feared may be auto-immune related adverse events. In early studies, several combined therapies have shown promising levels of safety and efficacy, particularly in hepatocellular carcinoma. This review provides a comprehensive and up-to-date overview of results of combined therapies for primary and secondary liver malignancies. Recent advances and future perspectives will be discussed.

show abstract

“…Pragmatically, the main difficulty in planning similar interventions, is the involvement of interventional radiologists, oncologists and laparoscopic surgeons in clinical trials. In fact, despite the right tools to reach almost every district in the body and inject tumor lesions with great precision and efficacy are available, these professionals are still hard to find except at very few excellence centers worldwide [71].…”

Section: Perspectives and Challengesmentioning

confidence: 99%

Boosting effect of pre-existing immunity on anti-cancer immunotherapies

Conti¹

2021

Frontiers Drug Chemistry Clinical Res

View full text Add to dashboard Cite

Intratumoral application of intact microbes and/or foreing antigens is a promising strategy in anti-cancer immunotherapy since, after the induced immune activation, antigen spread toward tumor-associated antigens and/or neo-antigens can generate an anti-tumor vaccine effect. However, the strong immunosuppressive nature of the tumor microenvironment (TME) has been shown most often to curb the mounting of an effective immune response. By examining the literature, we found evidence that pre-existing immunity to foreign antigens has a crucial role in determining the actual degree of immune activation obtainable. Therefore, assessing or even voluntarily inducing pre-existing immunity to specific foreign antigens can help develop successful immunotherapy. Furthermore, pre-existing immunity to common pathogens developed by previous infection and/or vaccination could be exploited to turn cold tumors into hot ones, a most desired condition for successful checkpoint inhibitor based anti-cancer immunotherapy.

show abstract

Immuno-Oncology in Cancer Care is a Fantastic Opportunity for Interventional Oncology: IO4IO (Interventional Oncology for Immuno-Oncology) Initiative

Cited by 7 publications

References 10 publications

Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience

Renal cell carcinoma lung metastases treated by radiofrequency ablation integrated with systemic treatments: over 10 years of experience

Synergizing liver systemic treatments with interventional oncology: friend or foe?

Boosting effect of pre-existing immunity on anti-cancer immunotherapies

Contact Info

Product

Resources

About